Embody is developing next generation regenerative products to address serious tendon and ligament injuries with a focus on sports medicine patients. Funded with over $15 million non-dilutive funding from DARPA and the US Army, we will secure FDA 510(k) clearance on our Tapestry collagen-based implant in Q1 2020. We raised $3.6 million in 2018 to fund commercial planning and will raise $3 to $4 million in Q1 2020 to fund commercial launch.